Holocene Advisors
VRTX icon

Holocene Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Holocene Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-451,300
Closed -$118M – 1022
2022
Q1 		$118M Buy
+451,300
New +$107M 0.61% 51

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Holocene Advisors's VRTX Position: Q1 2026 in Review

Holocene Advisors increased its Vertex Pharmaceuticals (VRTX) stake by 4,475% in Q1 2026, buying an estimated $30.8M and bringing the position to 67,618 shares worth $30.2M. The position accounts for 0.07% of the portfolio, ranked #232.

Holocene Advisors first reported a position in VRTX in Q1 2018 and has held it in 15 quarters since. The position peaked at $141M in Q2 2022. 1,689 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Holocene Advisors held 67,618 shares of Vertex Pharmaceuticals worth $30.2M as of Q1 2026.
  • Holocene Advisors bought 66,140 Vertex Pharmaceuticals shares in Q1 2026, an estimated $30.8M.
  • Vertex Pharmaceuticals made up 0.07% of Holocene Advisors's portfolio in Q1 2026, its #232 holding.
  • Holocene Advisors first reported a position in Vertex Pharmaceuticals in Q1 2018 and has held it in 15 quarters since.
  • Holocene Advisors's Vertex Pharmaceuticals position peaked at $141M in Q2 2022.
  • 1,689 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Holocene Advisors's 13F filing for Q1 2026, filed 15 May 2026.